Total Quarterly Revenue of $4 million, up 9% year-over-year.Record Backlog of $54.9 million.Gross Margin of 42%.Cost-Cutting ...

Donald Trump's reelection as President will impact the energy industry, but maybe not as expected. Energy, trade, regulatory, ...

A remarkable, inspiring, and influential political, financial, philanthropic, and religious figure, Montefiore led a life ...

Q3 2024 Earnings Conference Call November 7, 2024 9:00 AM ETCompany ParticipantsPeter Cannito - Chairman, Chief ...

As the British & Irish Lions prepare to embark on the next chapter in their storied history, the World Rugby Museum has laid ...

NEW YORK, Nov. 06, 2024 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today reported financial results for the third quarter of 2024 and raised full year 2024 guidance for Portfolio Receipts.

VANCOUVER, British Columbia, Nov. 04, 2024 (GLOBE NEWSWIRE) -- Diversified Royalty Corp. (TSX: DIV and DIV.DB.A) (the “Corporation” or “DIV”) is pleased to announce that its board of ...

Below, we’ll dig into exclusive resorts that are primarily for the ultra-rich, based on their reputation and price. Prices ...

VANCOUVER, British Columbia, Nov. 04, 2024 (GLOBE NEWSWIRE) — Diversified Royalty Corp. (TSX: DIV and DIV.DB.A) (the “Corporation” or “DIV”) is pleased to announce that its board of directors has ...

KalVista Pharmaceuticals, Inc. (NASDAQ: KALV) (“KalVista”), today announced the closing of a synthetic royalty financing ... with a Prescription Drug User Free Act (“PDUFA”) target action ...

Nov. 04, 2024 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) and Syndax Pharmaceuticals (Nasdaq: SNDX) today announced that Royalty Pharma has entered into a $350 million synthetic royalty ...